MDT
89.64
-0.03%↓
VEEV
281.99
+1.94%↑
A
113.98
-2.16%↓
WBA
11.48
-0.26%↓
HQY
97.59
-2.48%↓
MDT
89.64
-0.03%↓
VEEV
281.99
+1.94%↑
A
113.98
-2.16%↓
WBA
11.48
-0.26%↓
HQY
97.59
-2.48%↓
MDT
89.64
-0.03%↓
VEEV
281.99
+1.94%↑
A
113.98
-2.16%↓
WBA
11.48
-0.26%↓
HQY
97.59
-2.48%↓
MDT
89.64
-0.03%↓
VEEV
281.99
+1.94%↑
A
113.98
-2.16%↓
WBA
11.48
-0.26%↓
HQY
97.59
-2.48%↓
MDT
89.64
-0.03%↓
VEEV
281.99
+1.94%↑
A
113.98
-2.16%↓
WBA
11.48
-0.26%↓
HQY
97.59
-2.48%↓
24h
Current
Min
7.57
Max
7.89
Income | -13M 4.6M |
---|---|
Sales | 126M 2.7M |
Profit margin | 169.368 |
Employees | 225 |
EBITDA | 77M -14M |
Recommendations | Buy |
---|---|
12 Months Forecast | +23.92% upside |
Next Earnings | 5 Aug 2025 |
---|
Market Cap | 31M |
---|---|
Previous open | 12.01 |
Previous close | 7.61 |
By Acuity
50%
50%
154 / 376 Healthcare
By Trading Central
Confidence
Bearish Evidence
0.306 / 0.33939 Support & Resistance
Past performance is not a reliable indicator of future results.
20 Feb 2025, 11:34 UTC
FibroGen: Co. Maintains Its Rights to Roxadustat in U.S. and in All Markets Not Licensed to Astellas >FGEN
DJ
Read
20 Feb 2025, 11:34 UTC
FibroGen: Upon Closing, AstraZeneca Will Obtain All Rights to Roxadustat in China >FGEN
DJ
Read
20 Feb 2025, 11:33 UTC
FibroGen: Following Close of Transaction, Co. Will Repay Term Loan Facility to Investment Funds Managed by Morgan Stanley Tactical Value >FGEN
DJ
Read
20 Feb 2025, 11:33 UTC
FibroGen; Will Receive Enterprise Value of $85M Plus FibroGen Net Cash Held in China at Closing, Currently Estimated to Be About $75M >FGEN
DJ
Read
20 Feb 2025, 11:31 UTC
FibroGen: To Continue to Advance Its Oncology Pipeline, With Initiation of Phase 2 Monotherapy Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer in 2Q 2025 >FGEN
DJ
Read
20 Feb 2025, 11:30 UTC
FibroGen Announces Sale of FibroGen China to AstraZeneca for About $160M
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 10 USD 23.92%
High 10 USD
Low 10 USD
Based on 2 Wall Street analysts offering 12 month price targets forFibroGen Inc - Dist in the last 3 months.
By TipRanks
Buy
2 ratings
1
Buy
1
Hold
0
Sell
Based on 2 analysts giving stock ratings to FibroGen Inc - Dist in the past 3 months.
By Trading Central
Short Term
Bearish Evidence
Recent bearish events outweigh bullish events.
Intermediate Term
Weak Bearish Evidence
Bearish events outweigh bullish events.
Long Term
Weak Bearish Evidence
There is one bearish event.
By Acuity
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$